Extramedullary intracranial localization of multiple myeloma and treatment with novel agents
Cancer, 09/09/2011
Gozzetti A et al. – Multivariate analysis showed poor survival for patients with beta 2–microglobulin and better survival for patients achieving complete remission or a very good partial remission (CR+VGPR). The overall data highlight the relevance of therapy with new drugs in intracranial myeloma, providing a framework for future clinical trials.







